Spaceflight as a cancer research catalyst Jessica Pham ∙ Inge van der Werf ∙ Karla Mack ∙ Catriona Jamieson ++... ++

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00135-X/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-8Q4cO_EP5XL0NAa79vit0clMk0Nfa98RKJs9xRiqRZykSBJMhPjenGPdpzvLpH9ftixGIX1H-WZQfG-GndpF2-_YjTqg&_hsmi=413524147&utm_content=413505366&utm_source=hs_email Editorial p393 The promise of telesurgery in oncology The Lancet Oncology https://www.thelancet.com/journals/lanonc/issue/vol27no4/PIIS1470-2045(26)X2003-4 A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR) Emily Alger, BSc MMathStata ∙ Antoine Regnault, PhDb ∙ Amylou C Dueck, PhDc ∙ Madeline Pe, PhDd ∙ Michael J Grayling, PhDe ∙ Melanie J Calvert, PhDf,g,h,i,j,k ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00018-5/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-8b0PziXdPTfEP9Pz9dPzsazLhT3X29Al55DAE5WIL0oRHq2IezgZuqFPbHXBeOBghxISZk1NGz2E8SzDCQNx5sUkXRAA&_hsmi=413524147&utm_content=413505366&utm_source=hs_email Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial Hua Zhong, MDa,* ∙ Jing Wang, MMb,* ∙ Runxiang Yang, MMc,* ∙ Yongzhong Luo, BMd,* ∙ Wei Zuo, MMe,* ∙ Wei Zhang, MDa,* ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00049-5/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-88Xwt1YPjnisiILnX4Ij5mzE5eZayjeXtUX29tfwsSp8NrnjYvonzSqMEsQgWSV-HmV6pcW6b-ilsqlF5hf0u2LlsM4A&_hsmi=413524147&utm_content=413505366&utm_source=hs_email